Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.00    0.00 (0.00%)
Bid:
7.50
Ask:
8.50
Spread: 1.00 (13.333%)
Market Cap: £52.42m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

New Nuclear Security Orders

28 May 2025 07:00

RNS Number : 3101K
Kromek Group PLC
28 May 2025
 

28 May 2025

 

Kromek Group plc 

("Kromek" or the "Group") 

 

New Nuclear Security Orders

Two orders to supply D3 series detectors to a European and a US customer

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has received two orders to supply its D3 series of detectors for use by a European and a US customer.

 

The orders, valued together at approximately $900k, are for immediate delivery. The European customer is dedicated to fostering civilian science and technology partnerships aimed at mitigating global CBRN security risks and advancing non-proliferation efforts. The US customer is a leading supplier of integrated products working in the defence and security sector with a history of implementing innovative security solutions. 

 

The customers will receive the Group's D3 series of detectors to enhance their capabilities in the timely detection of radiation levels, as well as to facilitate data collection and processing and real-time data transmission. This will enable better informed decision-making and rapid responses to potential threats to national safety and security.

 

Arnab Basu, Chief Executive Officer of Kromek, said: "We are pleased to announce the receipt of these new orders that underscore our continued commitment to providing advanced detection solutions for emergency response services. Our proprietary technology is instrumental in mitigating radiological and nuclear threats through rapid, reliable detection and real-time data transmission capabilities.

 

"In an environment marked by ongoing geopolitical uncertainty, demand for our solutions continues to grow, highlighting Kromek's vital role in supporting global safety and security efforts. These orders reflect the increasing trust in our innovative technologies and further solidify Kromek's position as a leading provider in the critical security market."

 

For further information, please contact: 

 

Kromek Group plc 

Arnab Basu, CEO 

Paul Farquhar, CFO 

+44 (0)1740 626 060 

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance 

Tim Redfern - ECM

Michael Johnson - Sales

+44 (0)20 7220 0500 

 

Gracechurch Group (Financial PR) 

Harry Chathli/Claire Norbury/Henry Gamble 

+44 (0)20 4582 3500 

 

Kromek Group plc 

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFFVIEVIDFIE
Date   Source Headline
5th Feb 20247:00 amRNSKromek granted £1.3m under Horizon Europe scheme
30th Jan 20247:00 amRNSInterim Results
25th Jan 20247:00 amRNSKromek receives £1.4m CBRN order for EU stockpile
23rd Jan 20247:00 amRNSNotice of Results
18th Jan 20247:00 amRNSKromek receives $1.6m in advanced imaging orders
7th Nov 20237:00 amRNSCollaboration agreement with new CT partner
31st Oct 20237:00 amRNSKromek receives additional $1m in CBRN orders
26th Oct 20237:00 amRNSFirst US DHS Contract for Biosecurity for $5.9m
9th Oct 20234:59 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSHolding(s) in Company
28th Sep 202311:25 amRNSResult of AGM
28th Sep 20237:00 amRNSFinancing Update
14th Sep 20237:00 amRNSPartial Conversion of Convertible Loan Notes
12th Sep 20237:00 amRNSKromek detectors in new Spectrum Dynamics scanner
1st Sep 20235:00 pmRNSNotice of AGM and Publication of Annual Report
24th Jul 20237:01 amRNSFinal Results
24th Jul 20237:00 amRNSAppointment of Joint Broker
5th Jun 20237:00 amRNSNew $1.5m CBRN contract in Asia
31st May 20239:05 amRNSHolding(s) in Company
25th May 20232:48 pmRNSResult of Open Offer, General Meeting and TVR
10th May 20231:39 pmRNSNotice of Investor Webinar
5th May 20233:46 pmRNSPlacing, Subscription, Open Offer and Notice of GM
2nd May 20237:00 amRNSKromek receives medical imaging order of c.$1.4m
19th Apr 20237:00 amRNSKromek and Analogic Collaboration Agreement
18th Apr 20237:01 amRNSTrading Update
18th Apr 20237:00 amRNSSeven-Year Agreement with Tier 1 OEM
29th Mar 20237:00 amRNSKromek secures orders totalling over $1m
22nd Mar 20232:51 pmRNSHolding(s) in Company
31st Jan 20237:00 amRNSKromek awarded c. £2.5m by Innovate UK
31st Jan 20237:00 amRNSInterim Results
9th Jan 20237:00 amRNSKromek Secures $0.8m Order for D3S ID
19th Dec 20227:00 amRNSFurther agreement with Smiths Detection
15th Dec 20229:32 amEQSKromek Group 'delighted' with new contracts
12th Dec 20227:00 amRNSKromek wins £1.5m in nuclear security contracts
16th Nov 20227:00 amRNSAward of £5m bio-threat contract by UK Government
10th Nov 20227:00 amRNSKromek awarded US nuclear security contract
17th Oct 202211:42 amRNSKromek detectors used in digital SPECT/CT scanner
28th Sep 202212:27 pmRNSResult of AGM
2nd Sep 20225:26 pmRNSNotice of AGM and Publication of Annual Report
23rd Aug 202211:10 amRNSFundraising of £1.14 million
5th Aug 20227:00 amRNSFundraising of £1.7m
3rd Aug 20222:05 pmRNSSecond Price Monitoring Extn
3rd Aug 20222:00 pmRNSPrice Monitoring Extension
2nd Aug 20227:00 amRNSFinal Results
2nd Aug 20227:00 amRNSKromek wins over $750k in new orders
7th Jul 20227:00 amRNSKromek enters agreement with Smiths Detection Inc.
25th May 20227:00 amRNSNew Nuclear Security order from US federal entity
16th May 202212:07 pmRNSDirector Share Purchase
16th May 20227:00 amRNSAppointment of Nominated Adviser and Broker
16th May 20227:00 amRNSBusiness and Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.